The survival benefit for patients with acute respiratory distress syndrome (ARDS) due to extracorporeal membrane oxygenation (ECMO) treatment invites consideration of whether ECMO might provide an important medical countermeasure for ARDS resulting from natural hazards or acts of terrorism. Anthrax spores, bioengineered or native avian flu strains, or chemical agents (such as chlorine gas and its derivatives) can all lead to lung injury with resulting ARDS. A framework is needed for ECMO if it is to be incorporated into our comprehensive emergency preparedness programmes.

ECMO provides continuous circulatory support or oxygenation to patients with cardiac failure and pulmonary failure. It is already established in the treatment of heart failure after cardiac surgery and has become increasingly accepted in the treatment of adults with lung injury who cannot be oxygenated by conventional means.[@bib1]

Technological advances, facilitating the implementation of ECMO in critical care, have improved outcomes for patients with ARDS.[@bib1] Improved technology combined with an increasing confidence in the use of ECMO from shared experiences reported at international meetings and through registries such as the Extracorporeal Life Support Organization (ELSO), has led to a substantial increase in its use ([figure](#fig1){ref-type="fig"} ). Our analysis of the US Nationwide Inpatient Sample (NIS) database shows that during the past decade, ECMO support after heart surgery (post-cardiotomy) and for respiratory failure has increased by more than six times.[@bib2] Severe acute respiratory syndrome (SARS) and H1N1 flu epidemics showed the need for lifesaving technologies and the ability of ECMO to potentially address this need in the treatment of ARDS;[@bib1] after its successful application in these outbreaks in 2007, rates of ECMO use for respiratory failure rapidly increased.[@bib3], [@bib4] FigureExtracorporeal membrane oxygenation use in the USA for post-cardiotomy failure and respiratory failure, 2001--11\*Respiratory failure is 15% in 2002. Data source: national inpatient sample data.[@bib2]

Portable ECMO devices are now available to allow ECMO initiation outside of a hospital setting. Some French, German, and Taiwanese centres have reported the feasibility of use of ECMO for cardiopulmonary arrest by trained interdisciplinary teams.[@bib5], [@bib6], [@bib7] The French field ECMO programme was established to specifically deal with the anticipated need for mobile ECMO in an H1N1 epidemic.[@bib5] This programme enhanced the possibility of incorporating ECMO into comprehensive emergency preparedness programmes as a medical countermeasure against epidemics or terrorist actions that could lead to ARDS. However, evidence on its use in this type of setting is limited. Although clinical information from case series, trials, and the ELSO registry provide some data, similar to other devices for disaster preparedness regimens, these devices cannot be fully tested until disaster situations arise. Bleeding, embolic, and infectious complications inherent in the use of ECMO might be increased when used in mass casualty settings in inexperienced hands. Indications for the use of ECMO could be inadvertently or erroneously expanded to include healthier patients in view of present enthusiasm for the technology because of its success in treating patients with H1N1 or SARS. Furthermore, ECMO might not be discontinued in futile cases whereby its further use leads to needless prolongation of patient discomfort and an inappropriate use of scare resources. All these factors make regulatory approval and consideration of ECMO as a medical countermeasure challenging; however, approval is needed to allow production and dissemination of sufficient devices for use in a public-health emergency.

From a regulatory perspective, the development of ECMO as a medical countermeasure needs to follow a different pathway to the usual process. It invites an even more radical change than the innovation pathway used by the US Food and Drug Administration.[@bib8] The type and number of patients affected by acts of bioterrorism or public-health emergencies that ECMO could treat is unknown; the device cannot be fully tested until those situations occur. For present approved devices, including ECMO, the approach to their use will be based on present clinical evidence, modelling, and expert opinion. For novel devices that are potential medical countermeasures, different types and thresholds of evidence are needed to accelerate approval. Appropriate systems of assessment need to be developed that can incorporate new concepts for using accumulated data as surrogate evidence of effectiveness (and safety) in medical countermeasure settings to allow ECMOs to be included into strategies of preparedness without delays. The amount and type of evidence will vary depending on whether the device used poses high clinical risks (eg, ECMO) or low clinical risks (eg, a novel type of wound dressing).

An important consideration for regulatory bodies in approving devices for public-health emergencies is defining the indications for their use to prohibit inappropriate and futile care. An infrastructure is needed to develop decision support systems for the use of these devices by health-care professionals and to develop simulations of their use in public health emergencies. Regulatory bodies should formulate new policies to ensure effective medical care is provided and that ethical concerns of health-care professionals, patients, and families are addressed. Formal definitions of circumstances that these devices should be used in would reduce the burden on physicians in deciding when a device is appropriate or when its use is futile.

Governmental and professional agencies worldwide should collaborate to build a framework for the most appropriate use of ECMO in public-health emergencies. Such a framework would need to include the evidence needed for regulatory approval and the various clinical, ethical, and financial aspects of ECMO availability and use. Combined global experiences from implementation of ECMO in influenza epidemics, as done already in many countries, could be the first phase of such a framework. In addition to this framework, the development of new systems for data collection and plans to incorporate new technologies, such as ECMO, is imperative. Guidance on the policy debate now could lead to a measured and thoughtful use of these technologies when a disaster occurs.
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